UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT of 1934

 

For the month of June 2016

 

001-37521

(Commission File Number)

 

INTEC PHARMA LTD.

(Translation of registrant’s name into English)

 

12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel

(+972) (2) 586-4657

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________

 

 

 

 

EXPLANATORY NOTE

 

On June 3, 2016, the Company issued a press release titled “Intec Pharma Announces Planned Management Changes.” A Copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 2 

 

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  INTEC PHARMA LTD.  
       
  By: /s/ Zeev Weiss  
    Name: Zeev Weiss  
   

Title: Chief Executive Officer

     
 Date: June 3, 2016      

 

 3 

 

 

EXHIBIT INDEX

 

Exhibit
No.
Description
   
99.1 Press release, dated June 3, 2016.

 

 4 

 

 

Exhibit 99.1

 

 

Intec Pharma Announces Planned Management Changes

 

Jerusalem, Israel, June 3, 2016 – Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Oren Mohar, company’s Chief Financial Officer, has resigned due to personal reasons.

 

Mr. Mohar said, “I would like to thank Zeev and the entire Intec team for enabling me to be part of this great company and I am highly confident in Intec's continued success in the coming years. I appreciate the opportunity that the Board of Directors provided me to serve the Company and its shareholders.”

 

Zeev Weiss, the Company’s Chief Executive Officer and director said: “During his term as company’s Chief Financial Officer, which also included the company’s initial public offering in the U.S, Oren made a significant contribution to Intec. Throughout Oren's time with Intec, he was well respected for his professionality and high level of integrity. We wish Oren success in the next stage of his career, and we thank him for his contribution.” 

 

Following Mr. Mohar’s resignation, Mr. Nir Sassi, Company’s VP Finance, will be appointed as the Chief Financial Officer of the company effective as of August 1, 2016.

 

About Intec Pharma Ltd.

 

Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, which is being developed for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, Accordion Pill Zaleplon, or AP-ZP, which is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance, and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers.

 

Contacts:

 

Zeev Weiss

Chief Executive Officer

(+972) (2) 586-4657

Zeev@intecpharma.com